Cargando…

Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study

AIM: This phase III, multicentre, randomized study (http://clinicaltrials.gov; NCT01958671) evaluated the efficacy and safety of ertugliflozin monotherapy in adults with inadequately controlled type 2 diabetes (glycated haemoglobin [HbA1c], 7.0% to 10.5% [53‐91 mmol/mol]) despite diet and exercise....

Descripción completa

Detalles Bibliográficos
Autores principales: Aronson, Ronnie, Frias, Juan, Goldman, Allison, Darekar, Amanda, Lauring, Brett, Terra, Steven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969239/
https://www.ncbi.nlm.nih.gov/pubmed/29419917
http://dx.doi.org/10.1111/dom.13251
_version_ 1783325931206606848
author Aronson, Ronnie
Frias, Juan
Goldman, Allison
Darekar, Amanda
Lauring, Brett
Terra, Steven G.
author_facet Aronson, Ronnie
Frias, Juan
Goldman, Allison
Darekar, Amanda
Lauring, Brett
Terra, Steven G.
author_sort Aronson, Ronnie
collection PubMed
description AIM: This phase III, multicentre, randomized study (http://clinicaltrials.gov; NCT01958671) evaluated the efficacy and safety of ertugliflozin monotherapy in adults with inadequately controlled type 2 diabetes (glycated haemoglobin [HbA1c], 7.0% to 10.5% [53‐91 mmol/mol]) despite diet and exercise. MATERIALS AND METHODS: The 52‐week study comprised a 26‐week, double‐blind, placebo‐controlled period (Phase A) during which 461 participants received placebo, ertugliflozin 5 mg/d or ertugliflozin 15 mg/d. This was followed by a 26‐week active‐controlled period (Phase B) during which participants in the placebo group who had not received glycaemic rescue therapy had blinded metformin added. Results to Week 52 are reported. Because of the use of metformin in Phase B, no statistical comparisons of efficacy were made between the ertugliflozin and placebo/metformin groups at Week 52. RESULTS: The mean (standard error) change from baseline to Week 52 in HbA1c was −0.9% (0.1) and −1.0% (0.1) in the ertugliflozin 5 and 15 mg groups, respectively. The proportions of participants with HbA1c <7.0% at Week 52 were 25.6% and 28.5%, respectively. Ertugliflozin reduced fasting plasma glucose, body weight and systolic blood pressure (SBP). The incidence of genital mycotic infections (GMIs) in females was significantly higher in both ertugliflozin groups (5 mg, 26.9%; 15 mg, 29.0%) vs the placebo/metformin group (9.9%), and in males was significantly higher in the 15 mg group (7.8%) vs the placebo/metformin group (1.2%). Ertugliflozin was not associated with increased incidence of urinary tract infections, symptomatic hypoglycaemia or hypovolaemia adverse events compared with placebo/metformin. CONCLUSIONS: Ertugliflozin treatment over 52 weeks improved glycaemic control and reduced body weight and SBP, but increased GMIs.
format Online
Article
Text
id pubmed-5969239
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-59692392018-05-30 Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study Aronson, Ronnie Frias, Juan Goldman, Allison Darekar, Amanda Lauring, Brett Terra, Steven G. Diabetes Obes Metab Original Articles AIM: This phase III, multicentre, randomized study (http://clinicaltrials.gov; NCT01958671) evaluated the efficacy and safety of ertugliflozin monotherapy in adults with inadequately controlled type 2 diabetes (glycated haemoglobin [HbA1c], 7.0% to 10.5% [53‐91 mmol/mol]) despite diet and exercise. MATERIALS AND METHODS: The 52‐week study comprised a 26‐week, double‐blind, placebo‐controlled period (Phase A) during which 461 participants received placebo, ertugliflozin 5 mg/d or ertugliflozin 15 mg/d. This was followed by a 26‐week active‐controlled period (Phase B) during which participants in the placebo group who had not received glycaemic rescue therapy had blinded metformin added. Results to Week 52 are reported. Because of the use of metformin in Phase B, no statistical comparisons of efficacy were made between the ertugliflozin and placebo/metformin groups at Week 52. RESULTS: The mean (standard error) change from baseline to Week 52 in HbA1c was −0.9% (0.1) and −1.0% (0.1) in the ertugliflozin 5 and 15 mg groups, respectively. The proportions of participants with HbA1c <7.0% at Week 52 were 25.6% and 28.5%, respectively. Ertugliflozin reduced fasting plasma glucose, body weight and systolic blood pressure (SBP). The incidence of genital mycotic infections (GMIs) in females was significantly higher in both ertugliflozin groups (5 mg, 26.9%; 15 mg, 29.0%) vs the placebo/metformin group (9.9%), and in males was significantly higher in the 15 mg group (7.8%) vs the placebo/metformin group (1.2%). Ertugliflozin was not associated with increased incidence of urinary tract infections, symptomatic hypoglycaemia or hypovolaemia adverse events compared with placebo/metformin. CONCLUSIONS: Ertugliflozin treatment over 52 weeks improved glycaemic control and reduced body weight and SBP, but increased GMIs. Blackwell Publishing Ltd 2018-02-23 2018-06 /pmc/articles/PMC5969239/ /pubmed/29419917 http://dx.doi.org/10.1111/dom.13251 Text en © 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Aronson, Ronnie
Frias, Juan
Goldman, Allison
Darekar, Amanda
Lauring, Brett
Terra, Steven G.
Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
title Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
title_full Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
title_fullStr Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
title_full_unstemmed Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
title_short Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
title_sort long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled t2dm despite diet and exercise: vertis mono extension study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969239/
https://www.ncbi.nlm.nih.gov/pubmed/29419917
http://dx.doi.org/10.1111/dom.13251
work_keys_str_mv AT aronsonronnie longtermefficacyandsafetyofertugliflozinmonotherapyinpatientswithinadequatelycontrolledt2dmdespitedietandexercisevertismonoextensionstudy
AT friasjuan longtermefficacyandsafetyofertugliflozinmonotherapyinpatientswithinadequatelycontrolledt2dmdespitedietandexercisevertismonoextensionstudy
AT goldmanallison longtermefficacyandsafetyofertugliflozinmonotherapyinpatientswithinadequatelycontrolledt2dmdespitedietandexercisevertismonoextensionstudy
AT darekaramanda longtermefficacyandsafetyofertugliflozinmonotherapyinpatientswithinadequatelycontrolledt2dmdespitedietandexercisevertismonoextensionstudy
AT lauringbrett longtermefficacyandsafetyofertugliflozinmonotherapyinpatientswithinadequatelycontrolledt2dmdespitedietandexercisevertismonoextensionstudy
AT terrasteveng longtermefficacyandsafetyofertugliflozinmonotherapyinpatientswithinadequatelycontrolledt2dmdespitedietandexercisevertismonoextensionstudy